SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

SOBRINO-COSSIO, Sergio et al. Proton pump inhibitors in gastroesophageal reflux disease: a custom-tailored therapeutic regimen. Rev. esp. enferm. dig. [online]. 2012, vol.104, n.7, pp.367-378. ISSN 1130-0108.  http://dx.doi.org/10.4321/S1130-01082012000700006.

    1. DeVault KR, Castell DO. Updated guidelines for diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200. [ Links ]

    2. Lacy BD, Weiser K, Chertoff J, Fass R. The diagnosis of gastroesophageal reflux disease. Am J Med 2010;123:583-92. [ Links ]

    3. El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997;113:755-60. [ Links ]

    4. Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-esophageal reflux disease. Alimentar Pharmacol Ther 1999;13:1621-30. [ Links ]

    5. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20. [ Links ]

    6. American Gastroenterological Association Institute Technical Review on the Management of Gastroesophageal Reflux Disease. Gastroenterol 2008;135:1392-413. [ Links ]

    7. Lee KC, Ma JD, Kuo GM. Pharmacogenomics: bringing the gap between science and practice. J Am Pharm Assoc 2010;50:e1-e17. [ Links ]

    8. Yang Y-X, Metz DC. Safety on proton pump inhibitor exposure. Gastroenterology 2010;139:1115-27. [ Links ]

    9. Sachs G. Review article: the clinical pharmacology of proton pump inhibitors. Alimentar Pharm Ther 2006;23(Supl. 2):2-8. [ Links ]

    10. Sachs G. Physiology of the parietal cell and therapeutic implications. Alimentar Pharm Ther 2003;23:68S-73S. [ Links ]

    11. Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of PPI. Pharmacogenomics 2011;12:873-88. [ Links ]

    12. Lindberg P, Nordberg P, Alminger T, Brandstrom A, Wallmark B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 1986;29:1327-9. [ Links ]

    13. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004;126:7800. [ Links ]

    14. Shin JM, Sachs G. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo. Biochem Pharmacol 2004;68:2117-27. [ Links ]

    15. Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002;123:1588. [ Links ]

    16. Vanderhoff BT, Tahbouh RM, Proton pump inhibitors: An update. Curr Gastroenterol Rep 2008;10:528-34. [ Links ]

    17. Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 and therapeutic response to proton pump inhibitors. Indian J Med Res 2008;126:521-30. [ Links ]

    18. Shin JM, Homerin M, Domagala F, Ficheux H, Sachs G. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo. Biochem Pharmacol 2006;71:837. [ Links ]

    19. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007;41(Supl. 2):S226-42. [ Links ]

    20. Katz PO. Review article: putting immediate-release proton-pump inhibitors into clinical practice -improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Ther 2005;22(Supl. 3):31-8. [ Links ]

    21. Bell NJV, Burget DW, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(Supl. 1):59-67. [ Links ]

    22. Howden CW, Jones DB, Peace KE, Burget DW, Hunt RH. The treatment of gastric ulcer with antisecretory drugs: relationship of pharmacological effect to healing rates. Dig Dis Sci 1988;33:619-24. [ Links ]

    23. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Alimentary Pharmacol Ther 1990; 4:25-33. [ Links ]

    24. Vanderhoff BT, Tahbouh RM, Proton pump inhibitors: An update. Curr Gastroenterol Rep 2008;10:528-34. [ Links ]

    25. Senn-Bilfinger J, editor. The Development of a New Proton-Pump Inhibitor: The Case History of Pantoprazole. In: Analogue-based Drug Discovery. Wiley-VCH; 2006. [ Links ]

    26. Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, Vavasseur F, Taccoen A, Fiorentini P, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005;21:575-82. [ Links ]

    27. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108:294-307. [ Links ]

    28. Scarpignato C, Pelosini I. Review article: the opportunities and benefits of extended acid suppression. Alimentar Pharm Ther 2006;23(Supl. 2):23-34. [ Links ]

    29. Wilder-Smith CH, Röhss K, Nilsson- Pieschl C, Junghard O, Nyman L. Comparison of esomeprazole (20, 40, 80 mg) versus lansoprazole (15, 30, 60 mg) on intragastric pH in healthy subjects. Gastroenterology 2003;124:A444 (abstract). [ Links ]

    30. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-40. [ Links ]

    31. Sáez V, Hernáez E, López L. Liberación controlada de fármacos. Aplicaciones Biomédicas. Revista Iberoamericana de Polímeros 2003;4:111-22. [ Links ]

    32. Gardner CR. Drug Delivery Systems: Fundamentals and Techniques. In: Johnson P, Lloyd-Jones JG, editors. Nueva York: VCH Publishers; 1988. p. 12. [ Links ]

    33. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001;15:355-70. [ Links ]

    34. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother 2005; 6:2501-10. [ Links ]

    35. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed- release tablets on nocturnal acid break- through in patients with symptomatic gastroesophageal reflux disease. Aliment Pharmacol Ther 2005;21:1467-74. [ Links ]

    36. Hepburn B, Goldlust B. Comparative effects of an omeprazole antacid complex-immediate release (OAC-IR) and omeprazole delayed-release (OME-DR) on omeprazole pharmacokinetics and gastric pH in healthy subjects. Gastroenterology 2003;124:A228. [ Links ]

    37. Howden CW. Review article: immediate- release proton-pump inhibitor therapy- potential advantages. Alimentary Pharmacol Ther 2005;22 (Supl. 3):25-30. [ Links ]

    38. Hunt RH, Armstrong D, Yaghoobi M, James C, Chen Y, Leonard J, et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008;28:187-99. [ Links ]

    39. Howden CW, Larsen LM, Perez MC, Palmer RD, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther 2009;30:895-907. [ Links ]

    40. Mayer MD, Vakily M, Witt G, Mulford DJ. The pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis (abstract S1095). Gastroenterology 2008;134(Supl. 1):A176. [ Links ]

    41. Vakily M, Zhang W, Wu J, Atkinson S, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009; 25:627-38. [ Links ]

    42. Lee RD, Mulford D, Wu J, Atkinson SN. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for doping flexibility with a Dual Delayed Release proton pump inhibitor. Aliment Pharmacol Ther 2010;31:1001-11. [ Links ]

    43. Morelli G, Chen H, Rossiter G, Rege B, Lu Y. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther 2011;33:845-54. [ Links ]

    44. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55. [ Links ]

    45. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004;20(4):399-406. [ Links ]

    46. Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on protom pump inhibitor therapy. Aliment Pharmacol Ther 2002;16:1309-16. [ Links ]

    47. Miehlke S, Madisch A, Kirsch C, Lindner F, Kuhlisch E, Laassà M, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily - a randomized, two-way crossover study. Aliment Pharmacol Ther 2005;21:963-7. [ Links ]

    48. Katz PO. Review article: acid-related disease - what are the unmet clinical needs? Aliment Pharmacol Ther 2006; 23(Supl. 2):9-22. [ Links ]

    49. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20. [ Links ]

    50. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endos-copy negative reflux disease. Cochrane Database Syst Rev 2006;3: CD002095. [ Links ]

    51. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96:27-34. [ Links ]

    52. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006; 24: 743-50. [ Links ]

    53. Armstrong D. Review article: gastric pH - the most relevant predictor of be-nefit in reflux disease? Aliment Pharmacol Ther 2004;20 (Supl. 5): 19-26. [ Links ]

    54. Morales-Arambula M, Sobrino-Cossio SR, Vargas JA, López-Alvarenga JC, Soto-Pérez JC, López-Colombo A, Teramoto-Matsubara O, et al. Nighttime GERD: Prevalence, symptom intensity and treatment response to a 4-week treatment with 40 mg of pantoprazole magnesium o.d. A report from the GERD Mexican Working Group. Gastroenterology 2009;136(5 Supl. 1):A-428. [ Links ]

    55. Frazzoni M, Conigliaro R, Melotti G. Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis. Aliment Pharmacol Ther 2011;33:601-6. [ Links ]

    56. Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004;20:413-21. [ Links ]

    57. Johnson DA, Hatlebakk JG, Klintenberg AC, Román J, Toth E, Stubberöd A, et al. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J Gastroenterol 2003;38:347-53. [ Links ]

    58. Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of GERD with proton pump inhibitors taken "on demand". Aliment Pharmacol Ther 2007;26:195-204. [ Links ]

    59. Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ 2006;332:11-7. [ Links ]

    60. Vaezi MF, Hicks DM, Abelson TI, Richter JE. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol 2003;1:333-44. [ Links ]

    61. Irwin RS, Curley FJ, French CL. Chronic cough: the spectrum of symptoms and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640. [ Links ]

    62. Soto-Pérez JC, Lopez-Alvarenga JC, Vargas JA, Sobrino-Cossio S, Teramoto OT, Higgins P, et al. Characterization of subjacent factors impacting intensity of extra-oesophageal symptoms of GORD. A report from the Mexican GORD Working Group. 16th United European Gastroenterology Week. 18-22 Oct 2008 Vienna, Austria Abstract No. P1058. [ Links ]

    63. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007;25:385-92. [ Links ]

    64. Ford GA, Oliver PS, Prior JS, Buttland RJ, Wilkinson SP. Omeprazole in the treatment of asthmatics with nocturnal and gastro-oesophageal reflux: A Placebo-controlled cross-over study. Postgrad Med J 1994; 70:350-4. [ Links ]

    65. Ulualp SO, Toohill RJ. Laryngopharyngeal reflux. State of the art diagnosis and treatment. Otolaryngol Clin North Am 2000;33:1-14. [ Links ]

    66. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005;100:283-9. [ Links ]

    67. Trifiro G, Corrao S, Alacqua M, Moretti S, Tari M, UVEC grupo, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-relate information sources. Br J Clin Pharmacol 2006;62(5):582-90. [ Links ]

    68. Horn JR, Hansten PD. Get to know an enzyme: CYP2C19. Available at: www.pharmacytimes.com/issue/pharmacy/2008/2008-05/2008-05-8538 [ Links ]

    69. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001;13:611-6. [ Links ]

    70. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17. [ Links ]

    71. Laine L, Hennekens Ch, MD. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010;105:34-41. [ Links ]

    72. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving Clopidogrel. Aliment Pharmacol Ther 2010;31:810-23. [ Links ]

    73. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904. [ Links ]

    74. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904. [ Links ]

    75. Moayyedi P. Hip fracture and proton pump inhibitors therapy. Position statement. Can J Gastroenterol 2008; 22: 855-6. [ Links ]

    76. Zelter A, Fernández JL, Bilder C, Rodríguez P, Wonaga A, Dorado F, et al. Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. Dig Dis Sci 2011; 56:1743-8. [ Links ]

    77. García-Alonso FJ, Martín-Mateos RM, González-Martín JA, Foruny JR, Vázquez-Sequeiros E, Boixeda de Miquel D. Gastric polyps: analysis of endoscopic and histological features in our center. Rev Esp Enferm Dig 2011;103:416-20. [ Links ]

    78. Savarino V, DiMario F, Scarpignato C. Proton pump inhibitors in GORD: An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009;59:135-53. [ Links ]

    79. Desta ZX, Shin JG, Flockhart DA. Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacokinet 2020;41: 913-58. [ Links ]